Imed Infinity Medical-Limited Partnership (IMED.TA)
Full history for every metric is available with a Kvantra account
Imed Infinity Medical-Limited Partnership (IMED.TA)
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | -1 | 0 | 0 | 0 | - |
| Operating profit | $m | -0 | -1 | ||||||
| Net profit | $m | -0 | -1 | -1 | -2 | -1 | -0 | -1 | - |
| EPS reported | $ | -0.03 | -0.09 | ||||||
| Operating cashflow per share | $ | -0.08 | -0.05 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.08 | -0.05 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -3 | -3 | ||||||
| Book value equity | $m | 6 | 6 | ||||||
| Book value per share | $ | 1.39 | 0.91 | ||||||
| Number of shares | m | 4.53 | 6.83 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.27 | 0.28 | ||||||
| P/S LTM | x | 0.00 | 3.19 | ||||||
| P/FCF LTM | x | -4.71 | -4.71 | ||||||
| EV/EBITDA LTM | x | 5.53 | 1.68 | ||||||
| EV/Sales LTM | x | 0.00 | -1.19 | ||||||
| Earnings Yield LTM | % | -8.49% | -3.82% | ||||||
| FCF Yield | % | -21.22% | -21.22% | ||||||
| Quality | |||||||||
| ROE | % | -2.33% | -1.09% | ||||||
| ROIC | % | -5.73% | -5.63% | ||||||
| Operating margin | % | 0.00% | -68.90% | ||||||
| Gross margin | % | 0.00% | +93.84% | ||||||
| FCF/Sales | % | - | -56.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | -100.00% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 13.87 | 8.76 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.46 | -0.44 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating as a research and development partnership, Imed Infinity Medical-Limited Partnership was founded in 2020 and is located in Tel Aviv, Israel. Its central mission involves providing capital for R&D ventures within the medical domain, especially those focused on digital health.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Imed Infinity Medical-Limited Partnership (IMED.TA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Operating as a research and development partnership, Imed Infinity Medical-Limited Partnership was founded in 2020 and is located in Tel Aviv, Israel. Its central mission involves providing capital for R&D ventures within the medical domain, especially those focused on digital health.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free